Cargando…
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
BACKGROUND: The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis of non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release of cfDNA into the bloodstream of NSCLC patients results from malignancy or chronic infl...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522634/ https://www.ncbi.nlm.nih.gov/pubmed/26125447 http://dx.doi.org/10.1038/bjc.2015.225 |
_version_ | 1782383983111176192 |
---|---|
author | Szpechcinski, A Chorostowska-Wynimko, J Struniawski, R Kupis, W Rudzinski, P Langfort, R Puscinska, E Bielen, P Sliwinski, P Orlowski, T |
author_facet | Szpechcinski, A Chorostowska-Wynimko, J Struniawski, R Kupis, W Rudzinski, P Langfort, R Puscinska, E Bielen, P Sliwinski, P Orlowski, T |
author_sort | Szpechcinski, A |
collection | PubMed |
description | BACKGROUND: The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis of non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release of cfDNA into the bloodstream of NSCLC patients results from malignancy or chronic inflammatory response. Consequently, the current diagnostic utility of plasma cfDNA quantification has not been thoroughly validated in subjects with chronic respiratory inflammation. Here we assess the effect of chronic respiratory inflammation on plasma cfDNA levels and evaluate the potential clinical value of this phenomenon as an early lung cancer diagnostic tool. METHODS: We measured plasma cfDNA concentrations in 50 resectable NSCLC patients, 101 patients with chronic respiratory inflammation (chronic obstructive pulmonary disease, sarcoidosis, or asthma) and 40 healthy volunteers using real-time PCR. RESULTS: We found significantly higher plasma cfDNA levels in NSCLC patients than in subjects with chronic respiratory inflammation and healthy individuals (P<0.0001). There were no significant differences in plasma cfDNA levels between patients with chronic respiratory inflammation and healthy volunteers. The cutoff point of >2.8 ng ml(−1) provided 90% sensitivity and 80.5% specificity in discriminating NSCLC from healthy individuals (area under the curve (AUC)=0.90). The receiver-operating characteristics curve distinguishing NSCLC patients from subjects with chronic respiratory inflammation indicated 56% sensitivity and 91% specificity at the >5.25-ng ml(−1) cutoff (AUC=0.76). CONCLUSIONS: We demonstrated that elevated plasma cfDNA levels in NSCLC resulted primarily from tumour development rather than inflammatory response, raising the potential clinical implications for lung cancer screening and early diagnosis. Further research is necessary to better characterise and identify factors and processes regulating cfDNA levels in the blood under normal and pathological conditions. |
format | Online Article Text |
id | pubmed-4522634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45226342016-07-28 Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease Szpechcinski, A Chorostowska-Wynimko, J Struniawski, R Kupis, W Rudzinski, P Langfort, R Puscinska, E Bielen, P Sliwinski, P Orlowski, T Br J Cancer Molecular Diagnostics BACKGROUND: The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis of non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release of cfDNA into the bloodstream of NSCLC patients results from malignancy or chronic inflammatory response. Consequently, the current diagnostic utility of plasma cfDNA quantification has not been thoroughly validated in subjects with chronic respiratory inflammation. Here we assess the effect of chronic respiratory inflammation on plasma cfDNA levels and evaluate the potential clinical value of this phenomenon as an early lung cancer diagnostic tool. METHODS: We measured plasma cfDNA concentrations in 50 resectable NSCLC patients, 101 patients with chronic respiratory inflammation (chronic obstructive pulmonary disease, sarcoidosis, or asthma) and 40 healthy volunteers using real-time PCR. RESULTS: We found significantly higher plasma cfDNA levels in NSCLC patients than in subjects with chronic respiratory inflammation and healthy individuals (P<0.0001). There were no significant differences in plasma cfDNA levels between patients with chronic respiratory inflammation and healthy volunteers. The cutoff point of >2.8 ng ml(−1) provided 90% sensitivity and 80.5% specificity in discriminating NSCLC from healthy individuals (area under the curve (AUC)=0.90). The receiver-operating characteristics curve distinguishing NSCLC patients from subjects with chronic respiratory inflammation indicated 56% sensitivity and 91% specificity at the >5.25-ng ml(−1) cutoff (AUC=0.76). CONCLUSIONS: We demonstrated that elevated plasma cfDNA levels in NSCLC resulted primarily from tumour development rather than inflammatory response, raising the potential clinical implications for lung cancer screening and early diagnosis. Further research is necessary to better characterise and identify factors and processes regulating cfDNA levels in the blood under normal and pathological conditions. Nature Publishing Group 2015-07-28 2015-06-30 /pmc/articles/PMC4522634/ /pubmed/26125447 http://dx.doi.org/10.1038/bjc.2015.225 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Molecular Diagnostics Szpechcinski, A Chorostowska-Wynimko, J Struniawski, R Kupis, W Rudzinski, P Langfort, R Puscinska, E Bielen, P Sliwinski, P Orlowski, T Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
title | Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
title_full | Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
title_fullStr | Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
title_full_unstemmed | Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
title_short | Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
title_sort | cell-free dna levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522634/ https://www.ncbi.nlm.nih.gov/pubmed/26125447 http://dx.doi.org/10.1038/bjc.2015.225 |
work_keys_str_mv | AT szpechcinskia cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT chorostowskawynimkoj cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT struniawskir cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT kupisw cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT rudzinskip cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT langfortr cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT puscinskae cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT bielenp cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT sliwinskip cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease AT orlowskit cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease |